These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 28703014

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy.
    Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M, Stasko J.
    Scand Cardiovasc J; 2018 Aug; 52(4):227-231. PubMed ID: 29842807
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans.
    Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M.
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):914-919. PubMed ID: 29050502
    [Abstract] [Full Text] [Related]

  • 9. Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
    Olivier CB, Weik P, Meyer M, Weber S, Diehl P, Bode C, Moser M, Zhou Q.
    J Thromb Thrombolysis; 2016 Aug; 42(2):161-6. PubMed ID: 26961375
    [Abstract] [Full Text] [Related]

  • 10. Laboratory assessment of the anticoagulant activity of dabigatran.
    Kyriakou E, Ikonomidis I, Stylos D, Bonovas S, Papadakis I, Nikolopoulos GK, Kokoris S, Kalantzis D, Economopoulou C, Kopterides P, Lekakis J, Tsantes AE.
    Clin Appl Thromb Hemost; 2015 Jul; 21(5):434-45. PubMed ID: 25525048
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dabigatran-related platelet thrombin response during triple anti-thrombotic therapy: A matter of time?
    Witkowski M, Steffens D, Hassanein A, Witkowski M, Kränkel N, Doerner A, Friebel J, Landmesser U, Rauch U.
    Thromb Res; 2017 Jan; 149():62-63. PubMed ID: 27907813
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effect of ex vivo anticoagulants on whole blood platelet aggregation.
    Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA.
    Platelets; 2009 Feb; 20(1):7-11. PubMed ID: 19172515
    [Abstract] [Full Text] [Related]

  • 17. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban.
    Wan H, Yang Y, Zhu J, Wu S, Zhou Z, Huang B, Wang J, Shao X, Zhang H.
    Blood Coagul Fibrinolysis; 2016 Dec; 27(8):882-885. PubMed ID: 26757012
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.
    Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M.
    J Thromb Thrombolysis; 2018 Oct; 46(3):393-398. PubMed ID: 30039454
    [Abstract] [Full Text] [Related]

  • 20. Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation.
    Tsuda K, Natori T, Shimizu M, Ishigaku Y, Oi K, Narumi S, Kamada A, Yoshida M, Oura K, Maeda T, Terayama Y.
    Thromb Res; 2020 May; 189():1-4. PubMed ID: 32120029
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.